Working collaboratively to provide creative solutions to protein challenges in drug discovery
NMR in Drug Discovery
NMR offers unique insights into protein structure, flexibility, and interactions. At Sygnature Discovery, we use NMR to illuminate binding events, guide fragment screening, and support hit validation, helping drug discovery teams make informed decisions faster.
VHL is an E3 ligase commonly used for targeted protein degradation. We have recently determined the structure of the VHL:Elongin C:Elongin B (VCB) complex with VH032 – a key building block for PROTACs.
Cryo-EM can offer unprecedented structural insight, but only with the right sample. Read about how we combine expert purification, quality control, and grid prep to ensure your protein is ready for high-resolution imaging.
TL1A is a cytokine associated with inflammatory disease. Here we present how we obtained high-quality crystals and used these to resolve a high-resolution structure of the TL1A trimer.
We recently presented a poster on pioneering Direct-to-Crystal(D2C) structural approaches that enable soaking VS hits, HTS hits, and crude reaction mixtures (CRMs) from Direct-to-Biology (D2B) experiments directly into crystals, even when reaction conversions are low.
